What is the 13F Pro Quality Score for NVST?

13F Pro ranks Envista Holdings Corp (NVST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NVST's current score at https://13fpro.ai/research/NVST (free sign-up required for the full ranking).

Which hedge funds own the most NVST stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NVST include BlackRock,, ARIEL INVESTMENTS,, DIMENSIONAL FUND ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NVST as soon as new 13F filings post.

Where does 13F Pro source NVST data?

All Envista Holdings Corp fundamentals and ownership data come directly from SEC EDGAR. Envista Holdings Corp files with the SEC under CIK 1757073. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NVST in?

Envista Holdings Corp (NVST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NVST research updated on 13F Pro?

NVST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Envista Holdings Corp(NVST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1757073 NVST stock profile & AI dashboard →

13F Pro Quality Score

49.8/100

Rank #1,493 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

41.5/100

Profitability

60.4/100

Balance Sheet

42.9/100

Earnings Quality

8.4/100

Free Cash Flow

49.5/100

Institutional Flow

51.5/100

Revenue Scale

67.3/100

Dilution Risk

48.9/100

NVST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Envista Holdings Corp (NVST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NVST at 49.8/100 on a 32-signal composite quality model, placing it at rank #1,493 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (8.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 48.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Envista Holdings Corp reports quarterly revenue of $705.5M, net income of $38.7M, an operating margin of 8.9%. Top institutional holders of NVST by reported 13-F value include BlackRock,, ARIEL INVESTMENTS,, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. NVST trades on the NYSE exchange and files with the SEC under CIK 1757073. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Envista Holdings Corp directly from SEC EDGAR. Envista Holdings Corp's 13F Pro composite quality score has ranged between 8 and 59 since 2021, currently 49.8 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Envista Holdings Corp

Quirks, history, and lore behind NVST — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · mid-cap · listed on the NYSE · headquartered in California.
2
The Numbers
Annual revenue in the range of $2.5–3 billion, with operations spanning more than 100 countries — most people have never heard of it, but their dentist almost certainly has.
3
The History
Spun off from Danaher Corporation in 2019, it was assembled from a collection of well-established dental technology businesses that Danaher had acquired over the years.
4
The Secret
Its portfolio covers the full arc of a dental visit — from imaging and diagnostics to implants and orthodontics — essentially a one-stop shop for the dental office supply chain.
5
The Lore
Its brands include Nobel Biocare, one of the most recognized names in dental implants, and Ormco, a major player in orthodontic brackets and wires.
6
The Giveaway
If your smile has ever been straightened, implanted, or X-rayed, there's a solid chance this Danaher dental spinout — ticker NVST — had something to do with it.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$705.5M

Net Income

Q1 2026

$38.7M

Free Cash Flow

Q1 2026

$-15.8M

Operating Margin

Q1 2026

8.9%

ROIC

Q1 2026

1.4%

D/E Ratio

Q1 2026

0.47

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.3% YoY

$2.72BFY 2025

FY22 $2.57BFY23 $2.57BFY24 $2.51BFY25 $2.72B

Net Income

+104.2% YoY

$47.0MFY 2025

FY22 $243.1MFY23 $-100.2MFY24 $-1.12BFY25 $47.0M

Operating Income

+120.8% YoY

$216.1MFY 2025

FY22 $319.2MFY23 $31.5MFY24 $-1.04BFY25 $216.1M

EPS (Diluted)

+104.3% YoY

$0.28FY 2025

FY22 $1.37FY23 $-0.60FY24 $-6.50FY25 $0.28

Total Assets

+6.1% YoY

$5.68BFY 2025

FY22 $6.59BFY23 $6.61BFY24 $5.35BFY25 $5.68B

Total Debt

-10.9% YoY

$1.45BFY 2025

FY22 $2.40BFY23 $1.74BFY24 $1.63BFY25 $1.45B

Op. Cash Flow

-18.1% YoY

$275.7MFY 2025

FY22 $182.7MFY23 $275.7MFY24 $336.5MFY25 $275.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$2.72B +8.3%	$2.51B -2.2%	$2.57B -0.1%	$2.57B +33.2%	$1.93B -15.6%	$2.28B
Net Income	$47.0M +104.2%	$-1.12B -1016.4%	$-100.2M -141.2%	$243.1M +630.0%	$33.3M -84.7%	$217.6M
Operating Income	$216.1M +120.8%	$-1.04B -3395.9%	$31.5M -90.1%	$319.2M +633.8%	$43.5M -81.5%	$235.7M
EPS (Diluted)	$0.28 +104.3%	$-6.50 -983.3%	$-0.60 -143.8%	$1.37 +585.0%	$0.20 -87.5%	$1.60
Total Assets	$5.68B +6.1%	$5.35B -19.0%	$6.61B +0.3%	$6.59B -4.2%	$6.88B +11.7%	$6.16B
Total Debt	$1.45B -10.9%	$1.63B -6.7%	$1.74B -27.4%	$2.40B -32.7%	$3.57B +167.7%	$1.33B
Operating Cash Flow	$275.7M -18.1%	$336.5M +22.1%	$275.7M +50.9%	$182.7M -35.6%	$283.9M -28.6%	$397.5M

AI Insight: NVST Financial Trends

Envista recovered from massive Q2 2024 losses to sustained profitability, but operating cash flow remains volatile with two quarters turning negative.

• Revenue recovered from $601M in Q3 2024 to $706M in Q2 2026, with Q4 2025 hitting peak of $751M.

• Operating income turned positive after Q2 2024's -$1,153M loss, reaching $73M in Q4 2025.

• Total debt decreased from $1,736M in Q2 2024 to $1,439M in Q2 2026.

⚠ Operating cash flow turned negative in Q1 2025 and Q2 2026 despite positive operating income.

⚠ Net income volatile with Q3 2025 posting -$30M loss after three consecutive profitable quarters.

AI Insight: NVST Ratio Trends

Envista's operating margin recovered from deeply negative Q2 2024 levels to 9.8% in Q4 2025, while ROIC improved from 1.8% to 6.4% over the same period.

• Operating margin surged from -182.2% in Q2 2024 to 9.8% in Q4 2025, showing strong operational recovery.

• ROIC expanded from 1.8% in Q3 2024 to 6.4% in Q4 2025, indicating improving capital efficiency.

• Debt-to-equity ratio declined from 0.55 in Q4 2024 to 0.47 in Q2 2026, strengthening balance sheet leverage.

• Net profit margin turned negative to -4.5% in Q3 2025 before recovering to 5.5% in Q2 2026.

⚠ Operating margin declined from 9.8% in Q4 2025 to 8.9% in Q2 2026, reversing recent improvement trend.

⚠ ROIC dropped from 6.4% in Q4 2025 to 5.5% in Q2 2026, first sequential decline since Q1 2025.

Get alerted when NVST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Envista Holdings Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NVST

BlackRock, Inc.
$452.9M17,852,827 sh
ARIEL INVESTMENTS, LLC
$275.6M10,863,592 sh
DIMENSIONAL FUND ADVISORS LP
$248.1M9,780,948 sh
MORGAN STANLEY
$223.1M8,793,137 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$192.0M7,566,721 sh
VANGUARD CAPITAL MANAGEMENT LLC
$185.7M7,318,581 sh
FRANKLIN RESOURCES INC
$174.9M6,894,025 sh
Gates Capital Management, Inc.
$136.1M5,362,711 sh
STATE STREET CORP
$132.7M5,228,758 sh
CITADEL ADVISORS LLC
$116.3M4,584,572 sh

Fund	Value	Shares
BlackRock, Inc.	$452.9M	17,852,827
ARIEL INVESTMENTS, LLC	$275.6M	10,863,592
DIMENSIONAL FUND ADVISORS LP	$248.1M	9,780,948
MORGAN STANLEY	$223.1M	8,793,137
VANGUARD PORTFOLIO MANAGEMENT LLC	$192.0M	7,566,721
VANGUARD CAPITAL MANAGEMENT LLC	$185.7M	7,318,581
FRANKLIN RESOURCES INC	$174.9M	6,894,025
Gates Capital Management, Inc.	$136.1M	5,362,711
STATE STREET CORP	$132.7M	5,228,758
CITADEL ADVISORS LLC	$116.3M	4,584,572

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NVST on your watchlist

Track score changes the day Envista Holdings Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NVST a good stock to buy?

13F Pro's AI-powered analysis of Envista Holdings Corp (NVST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVST are available on the NVST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NVST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Envista Holdings Corp's investment landscape.